Oscar Tendero

Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial

Alessandro Gronchi, Stefano Ferrari, Vittorio Quagliuolo et al. · The Lancet Oncology · 2017 · 489 citations

Medicine, Oncology, Surgery +17

Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups

Alessandro Gronchi, Emanuela Palmerini, Vittorio Quagliuolo et al. · Journal of Clinical Oncology · 2020 · 261 citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant chemotherapy in high‐risk soft tissue sarcomas: A Sarculator‐based risk stratification analysis of the ISG‐STS 1001 randomized trial

Sandro Pasquali, Emanuela Palmerini, Vittorio Quagliuolo et al. · Cancer · 2021 · 101 citations · Full text

Medicine, Oncology, Surgery +16

Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall

Alessandro Gronchi, Paolo Verderio, Antonino De Paoli et al. · Annals of Oncology · 2012 · 83 citations · Full text

Medicine, Oncology, Surgery +10

Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS)

Javier Martín‐Broto, Nadia Hindi, Josefina Cruz et al. · The Oncologist · 2018 · 61 citations · Full text

Medicine, Oncology, Surgery +17